| Writing About Experiences With Ovarian Cancer (NCT02593422) | University of Maryland, College Park | 2015-04-01 |
| Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE) (NCT02374827) | University of Alabama at Birmingham | 2015-04-01 |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (NCT02354586) | Tesaro, Inc. | 2015-03-23 |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors (NCT02367352) | Millennium Pharmaceuticals, Inc. | 2015-03-19 |
| BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment (NCT02326844) | National Cancer Institute (NCI) | 2015-03-02 |
| Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer (NCT02278783) | University of Utah | 2015-03-01 |
| Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer (NCT02399592) | Vejle Hospital | 2015-03-01 |
| Study of Predictive Factors of Chemoresistance in Ovarian Cancer (NCT02878122) | Rennes University Hospital | 2015-03-01 |
| Prevalence of BRCA in Patients With Ovarian Cancer (NCT02222883) | AGO Research GmbH | 2015-03-01 |
| Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (NCT02354131) | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2015-02-15 |
| Short-course HIPEC in Advanced Epithelial Ovarian Cancer (NCT02249013) | Professor Fernando Figueira Integral Medicine Institute | 2015-02-01 |
| Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) (NCT02346955) | Famewave Ltd. | 2015-02-01 |
| Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy (NCT02372864) | University Medical Center Groningen | 2015-02-01 |
| Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer (NCT02117817) | Rutgers, The State University of New Jersey | 2015-02-01 |
| A Trial of Vigil for Participants With Ovarian Cancer (NCT02346747) | Gradalis, Inc. | 2015-02-01 |
| A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (NCT02203513) | National Cancer Institute (NCI) | 2015-01-20 |
| The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian Cancer (NCT02856841) | Cairo University | 2015-01-01 |
| The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients (NCT03019315) | National Taiwan University Hospital | 2015-01-01 |
| Circulating Tumor DNA Exposure in Peripheral Blood (NCT03517332) | Quantgene Inc. | 2015-01-01 |
| Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (NCT02321228) | University Medical Center Nijmegen | 2015-01-01 |
| Cancer Prevention in Women With a BRCA Mutation (NCT02225015) | Women's College Hospital | 2015-01-01 |
| Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy (NCT02307500) | Istituto Clinico Humanitas | 2014-12-01 |
| Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer (NCT02317705) | On Target Laboratories, LLC | 2014-12-01 |
| hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (NCT02960594) | Inovio Pharmaceuticals | 2014-12-01 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) (NCT02327078) | Incyte Corporation | 2014-11-26 |
| Yoga Practice for Breast or Ovarian Cancer Patients (NCT02305498) | Memorial Sloan Kettering Cancer Center | 2014-11-24 |
| Venous Thromboembolic Complications in Ovarian Cancer (NCT02480790) | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | 2014-11-01 |
| Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention (NCT02287519) | Dana-Farber Cancer Institute | 2014-11-01 |
| Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers (NCT02269293) | Memorial Sloan Kettering Cancer Center | 2014-10-13 |
| Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE) (NCT02312167) | Institut Mutualiste Montsouris | 2014-10-01 |
| Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors (NCT02262455) | Santa Maria Biotherapeutics | 2014-10-01 |
| Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer (NCT02237690) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 2014-09-01 |
| PTX-200 and Carboplatin in Ovarian Cancer (NCT01690468) | Prescient Therapeutics, Ltd. | 2014-09-01 |
| DOD Long-Term Survivors of Ovarian Cancer (NCT02321735) | Massachusetts General Hospital | 2014-09-01 |
| PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer (NCT02055690) | The Christie NHS Foundation Trust | 2014-09-01 |
| Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging (NCT02792959) | Institut Bergonié | 2014-08-01 |
| Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients (NCT02785887) | Azienda USL 4 Prato | 2014-08-01 |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (NCT01610869) | University College, London | 2014-08-01 |
| Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies (NCT01880996) | Sheba Medical Center | 2014-08-01 |
| Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (NCT02118285) | Masonic Cancer Center, University of Minnesota | 2014-07-28 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers (NCT02178722) | Incyte Corporation | 2014-07-17 |
| Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) (NCT02163720) | ARCAGY/ GINECO GROUP | 2014-07-10 |
| Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures. (NCT02221076) | Mauna Kea Technologies | 2014-07-01 |
| Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) (NCT02179515) | National Cancer Institute (NCI) | 2014-06-28 |
| Biomarkers for Gynecologic Cancer (NCT02178462) | Ajinomoto Co., Inc. | 2014-06-01 |
| LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma (NCT02083536) | University of Miami | 2014-05-01 |
| Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome. (NCT02341118) | University Health Network, Toronto | 2014-05-01 |
| Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT02121990) | Memorial Sloan Kettering Cancer Center | 2014-04-21 |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (NCT01968213) | pharmaand GmbH | 2014-04-07 |
| Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients (NCT02490488) | AB Science | 2014-04-01 |
| Blood Collection From People With Ovarian Cancer (NCT02063464) | National Cancer Institute (NCI) | 2014-03-10 |
| Photoacoustic Imaging of the Ovary (NCT02110277) | UConn Health | 2014-03-01 |
| Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System (NCT04817501) | Tomsk National Research Medical Center of the Russian Academy of Sciences | 2014-02-14 |
| A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (NCT01991210) | Genentech, Inc. | 2014-02-06 |
| Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) (NCT02054351) | Ganymed Pharmaceuticals GmbH | 2014-02-06 |
| Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass (NCT02109367) | Southern Illinois University | 2014-02-01 |
| A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer (NCT02042885) | Otsuka Novel Products GmbH | 2014-01-01 |
| Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer (NCT02092363) | OncoMed Pharmaceuticals, Inc. | 2014-01-01 |
| Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer (NCT02125513) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2014-01-01 |
| Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin (NCT02017678) | Andrea McCart | 2014-01-01 |
| Ensuring Communication in Hospice by Oncology Study (ECHO) (NCT02069769) | Massachusetts General Hospital | 2014-01-01 |
| DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics (NCT02288676) | McGill University | 2014-01-01 |
| Regional Distribution Mapping of Lymph Node Metastasis in Epithelial Ovarian Cancer (NCT06853730) | Xu Huishan | 2014-01-01 |
| A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (NCT01975831) | Ludwig Institute for Cancer Research | 2013-12-19 |
| Predictive Clinical and Biological Parameters in Gynecological Cancer (NCT01977274) | Institut Paoli-Calmettes | 2013-12-01 |
| EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer (NCT02001272) | Hospices Civils de Lyon | 2013-12-01 |
| A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (NCT02033551) | AbbVie | 2013-12-01 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (NCT02009449) | Eli Lilly and Company | 2013-11-15 |
| Tivozanib As Maintenance Therapy In GYN (NCT01972516) | Dana-Farber Cancer Institute | 2013-11-01 |
| The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (NCT01556841) | University College, London | 2013-11-01 |
| Integrated Cancer Repository for Cancer Research (NCT02012699) | University of Nebraska | 2013-11-01 |
| Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma (NCT02039388) | Medical University of Vienna | 2013-11-01 |
| Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer (NCT02132988) | Mackay Memorial Hospital | 2013-11-01 |
| A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-11-01 |
| EC17 for Intraoperative Imaging in Occult Ovarian Cancer (NCT02000778) | University of Pennsylvania | 2013-11-01 |
| Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. (NCT01953107) | Sunnybrook Health Sciences Centre | 2013-11-01 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (NCT01891344) | pharmaand GmbH | 2013-10-30 |
| Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (NCT02019524) | COL George Peoples, MD, FACS | 2013-09-30 |
| Hula, a Physical Activity Intervention for Female-Cancer Survivors (NCT02351479) | University of Hawaii | 2013-09-01 |
| ONSD According to the Position During Laparoscopy (NCT01937104) | Chosun University Hospital | 2013-09-01 |
| Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve (NCT01888159) | Karlstad Central Hospital | 2013-09-01 |
| Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors (NCT01831089) | PharmaMar | 2013-09-01 |
| LDE225 and Paclitaxel in Solid Tumors (NCT01954355) | Swiss Cancer Institute | 2013-09-01 |
| Assessment of Paclitaxel-Induced Neuropathy (NCT01953159) | University of Chicago | 2013-08-29 |
| A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (NCT02093871) | ThermalCore Inc | 2013-08-01 |
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer (NCT01881451) | British Columbia Cancer Agency | 2013-08-01 |
| Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer (NCT01889615) | Odense University Hospital | 2013-08-01 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| Phase I Trial of VS-6766 Alone and in Combination With Everolimus (NCT02407509) | Royal Marsden NHS Foundation Trust | 2013-06-17 |
| An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1) (NCT01863693) | Hoffmann-La Roche | 2013-05-10 |
| Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families (NCT03119285) | University of Washington | 2013-04-01 |
| NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) (NCT03804866) | AGC Biologics S.p.A. | 2013-03-01 |
| PET-CT vs. Integrated MR-PET Scanning of GYN Cancers (NCT01779128) | Massachusetts General Hospital | 2013-03-01 |
| Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients (NCT01834469) | Jules Bordet Institute | 2013-03-01 |
| An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer (NCT02151370) | Hoffmann-La Roche | 2013-03-01 |
| Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer (NCT01826227) | Memorial Sloan Kettering Cancer Center | 2013-03-01 |
| Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer (NCT01778803) | Verastem, Inc. | 2013-02-26 |
| BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (NCT01669798) | AA Secord | 2013-02-01 |
| A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable (NCT01739218) | Hoffmann-La Roche | 2013-02-01 |
| Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01767675) | Memorial Sloan Kettering Cancer Center | 2013-01-08 |